Key Points
- Abbott director Daniel Starks purchased 10,000 shares on Feb. 4 at an average price of $108.73 (totaling $1,087,300), increasing his holdings to 6,738,817 shares (a 0.15% boost) per an SEC Form 4 filing.
- Dividend increased: Abbott raised its quarterly dividend to $0.63 from $0.59 (ex-dividend Jan. 15, payable Feb. 13), equal to a $2.52 annualized payout and about a 2.3% yield.
- Abbott reported Q4 EPS of $1.50 (in line) and revenue of $11.46B (below estimates), issued Q1 2026 guidance of $1.120–1.180 and FY2026 guidance of $5.550–5.800, and holds a consensus analyst rating of "Moderate Buy" with a $137.05 target.
Abbott Laboratories (NYSE:ABT - Get Free Report) Director Daniel Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares of the company's stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Abbott Laboratories Trading Up 1.6%
Shares of ABT opened at $110.86 on Friday. The stock's 50-day moving average price is $120.86 and its 200 day moving average price is $126.89. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The firm has a market capitalization of $192.77 billion, a price-to-earnings ratio of 29.80, a P/E/G ratio of 1.74 and a beta of 0.75.
Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.Abbott Laboratories's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.
Abbott Laboratories Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 67.74%.
Analyst Ratings Changes
A number of research analysts have commented on ABT shares. Citigroup cut their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a "buy" rating for the company in a research note on Friday, January 23rd. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, November 20th. Leerink Partners decreased their price target on Abbott Laboratories from $136.00 to $119.00 and set a "market perform" rating on the stock in a research note on Friday, January 30th. Barclays dropped their price objective on Abbott Laboratories from $169.00 to $142.00 and set an "overweight" rating for the company in a research note on Monday, February 2nd. Finally, Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a "buy" rating in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $137.05.
Read Our Latest Research Report on ABT
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ABT. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the 3rd quarter worth approximately $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories during the 3rd quarter worth $31,000. Finally, Anfield Capital Management LLC boosted its position in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after buying an additional 104 shares during the last quarter. 75.18% of the stock is owned by institutional investors.
Abbott Laboratories Company Profile
(
Get Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
